ARTICLE | Clinical News

Bausch + Lomb option to MIM-D3 terminated

September 12, 2014 2:40 AM UTC

Mimetogen Pharmaceuticals Inc. (Montreal, Quebec) said an option was terminated Aug. 31 that would have allowed the Bausch + Lomb Inc. unit of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) to take worldwide rights to dry eye candidate MIM-D3.

Bausch + Lomb paid an undisclosed amount for the option in 2013, allowing it to take the rights following top-line results from a Phase III trial of the small molecule mimetic of nerve growth factor (NGF). ...